Articles
-
Acknowledgment to reviewers of Journal of Translational Genetics and Genomics in 2022
J Transl Genet Genom 2023;7:1-2. DOI: 10.20517/jtgg.2023.03Editorial|Published on: 29 Jan 2023 -
The importance of genetics in an advanced integrative model of autism spectrum disorder
J Transl Genet Genom 2022;6:429-42. DOI: 10.20517/jtgg.2022.15AbstractGenes have long been considered to cause autism spectrum disorder (ASD). However, data obtained over ... MOREGenes have long been considered to cause autism spectrum disorder (ASD). However, data obtained over the last 10 years indicate that the true role of genetics in ASD and the cost-benefit ratio of genetic testing following an ASD diagnosis warrant further investigation. ASD is heterogeneous with high individual complexity, and new findings related to systemic alterations in ASD (in addition to genetics) should be considered when attempting to optimize patient health. However, for some people with ASD and their families, genetic testing can identify genetic mutations or chromosomic alterations. This review mainly considers recent research (the last 5 years) on the role of genetic factors in ASD and the importance of genetic testing in a new Advanced Integrative Model of ASD. LESS Full articlePerspective Review|Published on: 29 Dec 2022 -
Rationale for haploinsufficiency correction therapy in neurofibromatosis type 1
J Transl Genet Genom 2022;6:403-28. DOI: 10.20517/jtgg.2022.14AbstractNeurofibromatosis type 1 (NF1) is a genetic disorder with a wide range of manifestations and ... MORENeurofibromatosis type 1 (NF1) is a genetic disorder with a wide range of manifestations and severity. Currently, the few available NF1 treatments target specific manifestations, with no available therapies targeted to correct the underlying driver of all NF1 manifestations. Evidence supports that haploinsufficiency in NF1 caused by a decreased amount of wild-type (WT) neurofibromin in all NF1+/- cells directly causes or facilitates a range of NF1 manifestations. Consequently, NF1 haploinsufficiency correction therapy (NF1-HCT) represents a potentially effective approach to treat some NF1 manifestations. NF1-HCT would normalize the level of WT neurofibromin in all NF1-haploinsufficient cells, including those integral to the NF1 phenotype such as Schwann cells (SCs), melanocytes, neurons, bone cells, and cells of the tumor microenvironment. This would correct altered cellular signaling pathways and, in turn, restore normal function to cells with a retained WT allele. NF1-HCT will not restore WT neurofibromin in NF1-/- cells; however, by restoring function in the surrounding NF1+/- microenvironment cells, NF1-HCT is predicted to have a beneficial effect on NF1-/- cells. NF1-HCT is expected to have a clinical effect in some NF1 manifestations, as follows: (i) prevention, or delay of onset, of potential manifestations; and (ii) reversal, or halting/slowing progression, of established manifestations. This review describes the rationale for NF1-HCT, including specific NF1 considerations (e.g., NF1 clinical phenotype, neurofibromin function/regulation, NF1 mutational spectrum, genotype-phenotype correlation, and the impact of haploinsufficiency in NF1), HCT in other haploinsufficient diseases, potential NF1-HCT drug treatment strategies, and the potential advantages/challenges of NF1-HCT. LESS Full articleReview|Published on: 25 Oct 2022 -
Genetic risk and its role in primary prevention of CAD
J Transl Genet Genom 2022;6:388-402. DOI: 10.20517/jtgg.2022.07AbstractCoronary artery disease (CAD) is a pandemic disease and the number one cause of death ... MORECoronary artery disease (CAD) is a pandemic disease and the number one cause of death in the world. Predisposition to CAD is about 50% acquired and 50% genetic. CAD prevention has been proven in randomized clinical trials with statin therapy. However, primary prevention is limited by the lack of biomarkers to detect asymptomatic young individuals at risk. Traditional risk factors (TRFs) such as hypertension or Type 2 Diabetes are age-dependent and often not present until the sixth or seventh decade. In contrast, genetic risk determined at conception is potentially a biomarker to detect young individuals at risk for CAD. The first genetic risk variant for CAD (9p21) was discovered in 2007, and subsequently, over 200 risk variants for CAD were discovered. A genetic risk score (GRS) based on the genetic risk variants for CAD was evaluated in over one million individuals. Retrospective analysis of clinical trials assessing the effect of statin therapy showed that individuals with the highest GRS had the highest risk for cardiac events and also the most benefit from lowering cholesterol. In a recent study of 55,685 individuals, those with the highest GRS (20%) had a 91% higher risk for cardiac events. Furthermore, those with high genetic risk on a favorable lifestyle had 46% fewer cardiac events than those with an unfavorable lifestyle. The GRS is superior and independent of TRFs. Incorporation into clinical practice will be a paradigm shift in preventing this pandemic. LESS Full articleReview|Published on: 8 Oct 2022 -
Development and early evaluation of clinical decision support for long QT syndrome population screening
J Transl Genet Genom 2022;6:375-87. DOI: 10.20517/jtgg.2022.12AbstractAim: Long QT syndrome (LQTS) is an inherited condition that predisposes individuals to prolongation of ... MOREAim: Long QT syndrome (LQTS) is an inherited condition that predisposes individuals to prolongation of the QT interval and increased risk for Torsade de Pointes. Pathogenic variants in three genes - KCNH2, KCNQ1 and SCN5A - are responsible for most cases of LQTS, and recent advances in genetic testing have improved knowledge of the disease, increased access to follow-up, and reduced adverse cardiovascular outcomes. Methods: Based around our preemptive genetic screening platform which includes the three long QT genes listed above, we developed and implemented a clinical decision support (CDS) module that alerts prescribers whenever a QT-prolonging medication is ordered for patients with a genetic predisposition to LQTS. Results: Of the 13,777 individuals screened, twenty-seven tested positive for a pathogenic or likely pathogenic variant of KCNH2, KCNQ1 or SCN5A. In a subsequent early evaluation of the CDS and clinical processes, the number of QT-prolonging medications in this cohort decreased by 20% and new QT-prolonging medications were avoided in approximately 1/3 of new prescription orders. Conclusions: While long-term evaluation is needed, early data support the benefit of utilizing CDS in expanded roles, such as drug-gene-disease interactions where rare genetic variants intersect with everyday prescribing. LESS Full articleOriginal Article|Published on: 1 Sep 2022 -
The many roles of the Alzheimer-associated gene PM20D1
J Transl Genet Genom 2022;6:361-74. DOI: 10.20517/jtgg.2022.10AbstractPM20D1 is a little studied enzyme until recently, belonging to the mammalian M20 peptidase family, ... MOREPM20D1 is a little studied enzyme until recently, belonging to the mammalian M20 peptidase family, which catalyzes both the synthesis and hydrolysis of N-acyl amino acids (NAAs). NAAs are bioactive lipids biosynthesized from free fatty acids and free amino acids. These molecules have been associated with many biological functions; however, most of the biochemical mechanisms have not yet been described. The best-known biochemical mechanism is the one involved in thermogenesis, which also has implications for reactive oxygen species levels and cell preservation. In the last few years, genetic variation in PM20D1, as well as changes in its methylation and expression levels, have been reported to be associated with several disease phenotypes, including Alzheimer’s disease. In this review, we explore the current knowledge regarding the PM20D1 gene, including aspects such as its biology, potential functions, regulation of its expression, and role in different phenotypes such as Alzheimer’s disease, obesity, Parkinson’s disease, and several other disorders. LESS Full articleReview|Published on: 1 Sep 2022
See more
About The Journal
-
ISSN
2578-5281 (Online)
Publisher
OAE Publishing Inc.
Article Processing Charges
$900
-
Editor-in-Chief
Sanjay Gupta
Publishing Model
Gold Open Access
Copyright
Copyright is retained by author(s)
-
Publication Frequency
Quarterly
Indexing
Scopus (Accepted for Inclusion on June 11, 2022)
Open Archives
-
Portico
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/